Vaxil Bio Ltd.

As of June 30, 2026, Vaxil Bio Ltd. has 3.98M shares outstanding.

As of June 30, 2026, Vaxil Bio Ltd. maintains a current ratio of 17.97, meaning it holds 18.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vaxil Bio Ltd. posted a return on equity (ROE) of 40.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -27.06, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 39.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 40.21, useful for judging operating efficiency across full business cycles.

As of the close on October 20, 2026, Vaxil Bio Ltd.'s stock has declined approximately 61.43% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.31.

Over the twelve months ended June 30, 2026, Vaxil Bio Ltd. generated - - in revenue and converted that into 267,049.98 in net income, yielding earnings per share of 0.07. EBITDA reached -179,677.43, while operating income came in at -179,677.43.

These figures are as of June 30, 2026. Total book value stands at 841,313.12, with working capital of 358,650.23 providing operational flexibility.

Vaxil Bio Ltd. produced -187,428.22 in operating cash flow over the twelve months ended June 30, 2026.

Vaxil Bio Ltd.'s most recent stock split took place on May 19, 2025 with a 50:1 split ratio.